Evaluation of a large-scale aptamer proteomics platform among patients with kidney failure on dialysis
Yue Ren, Peifeng Ruan, Mark Segal, Mirela Dobre, Jeffrey R. Schelling, Upasana Banerjee, Tariq Shafi, Peter Ganz, Ruth F. Dubin, the CRIC Study Investigators · 2023
Read Evaluation of a large-scale aptamer proteomics platform among patients with kidney failure on dialysis by Yue Ren, Peifeng Ruan, Mark Segal, Mirela Dobre, Jeffrey R. Schelling, Upasana Banerjee, Tariq Shafi, Peter Ganz, Ruth F. Dubin, the CRIC Study Investigators (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10712847.txt.
Description
Yue Ren and co-authors, with the CRIC Study Investigators, checked the reliability of a platform that measures about five thousand blood proteins at once, in a 2023 study of dialysis patients. People with kidney failure die at high rates, and doctors lack good markers to tell who is at greatest risk. Before launching a large study, the team needed to know the platform's error levels.
They tested samples from forty dialysis patients and a larger kidney cohort, looking at repeatability within a run, between runs, and over a year. Variation stayed modest on all counts. The platform's readings for four known markers matched standard lab tests closely. Several proteins also stood out at higher levels in patients who later died.
Catalog record
| CREATOR | Yue Ren, Peifeng Ruan, Mark Segal, Mirela Dobre, Jeffrey R. Schelling, Upasana Banerjee, Tariq Shafi, Peter Ganz, Ruth F. Dubin, the CRIC Study Investigators |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |